Never miss an issue of Master Investor Magazine – sign-up now for free!
Shares in AIM-listed SalvaRX (LON:SALV) rose by 8.55% to 73p (as of 11:10 BST) after a clinical biotechnology firm in which it has an 8% holding announced positive trial results. Intensity Therapeutics said that it’s INT230-6 product had no dose limiting toxicity or serious adverse events and was shown to increase circulating T-Cells in cases of advanced solid tumours.
Intensity’s chief medical officer Dr Ian Walters said: “The study will continue to enroll patients with difficult-to-treat tumors as we explore higher doses. We look forward to adding more North American sites, as well as new centers outside the U.S. and Canada. In addition, we plan to move into combination arms with an anti-PD-1 antibody and begin Phase 2 expansion cohorts next year.“